Literature DB >> 27022116

Risk of Adverse Health and Social Outcomes Up to 50 Years After Wilms Tumor: The British Childhood Cancer Survivor Study.

Kwok F Wong1, Raoul C Reulen1, David L Winter1, Joyeeta Guha1, Miranda M Fidler1, Julie Kelly1, Emma R Lancashire1, Kathryn Pritchard-Jones1, Helen C Jenkinson1, Elaine Sugden1, Gill Levitt1, Clare Frobisher1, Michael M Hawkins2.   

Abstract

PURPOSE: Survivors of Wilms tumor (WT) are at risk for adverse health and social outcomes but risks beyond 30 years from diagnosis remain uncertain. We investigated the risks of adverse outcomes among 5-year survivors of WT, in particular, those between 30 and 50 years from diagnosis. PATIENTS AND METHODS: The British Childhood Cancer Survivor Study includes 1,441 5-year survivors of WT. We investigated cause-specific mortality, risk of subsequent primary neoplasms (SPNs), and, for those who completed a questionnaire, the extent of smoking and drinking, educational achievement, health status, and health service use compared with the general population.
RESULTS: Cumulative risk of death from all causes, excluding recurrence, increased substantially from 5.4% to 22.7% at 30 years and 50 years, respectively, after WT diagnosis-75% of excess deaths beyond 30 years from diagnosis were attributable to SPNs (50%) and cardiac diseases (25%). Digestive cancer, most frequently bowel, accounted for 41% of excess cancers beyond 30 years.
CONCLUSION: Between 30 and 50 years from diagnosis, survivors of WT are at a substantially increased risk of premature mortality, and 75% of excess deaths were accounted for by SPNs and cardiac diseases. Radiotherapy exposure was a risk factor for both outcomes. The proportion of patients with WT who are exposed to radiotherapy has reduced substantially in recent decades because of initiatives such as the SIOP WT 2001 clinical trial, which sought to reduce late effects; however, the majority of current survivors, who are at least 30 years from diagnosis, received radiotherapy. Surveillance of this group should focus on SPNs, in particular, bowel and breast cancers, and cardiac conditions.
© 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2016        PMID: 27022116     DOI: 10.1200/JCO.2015.64.4344

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  17 in total

1.  Prospective analysis of long-term renal function in survivors of childhood Wilms tumor.

Authors:  Marie A Neu; Alexandra Russo; Arthur Wingerter; Francesca Alt; Johanna Theruvath; Khalifa El Malki; Bettina Kron; Matthias Dittrich; Johannes Lotz; Raimund Stein; Rolf Beetz; Joerg Faber
Journal:  Pediatr Nephrol       Date:  2017-04-28       Impact factor: 3.714

2.  Kidney Outcomes and Hypertension in Survivors of Wilms Tumor: A Prospective Cohort Study.

Authors:  David I Chu; Abdulla M Ehlayel; Jill P Ginsberg; Kevin E Meyers; Maryjane Benton; Melissa Thomas; Claire Carlson; Thomas F Kolon; Gregory E Tasian; Jason H Greenberg; Susan L Furth; Michelle R Denburg
Journal:  J Pediatr       Date:  2020-12-05       Impact factor: 4.406

3.  MYCN gene polymorphisms and Wilms tumor susceptibility in Chinese children.

Authors:  Xiaokai Huang; Jie Zhao; Jinhong Zhu; Shanshan Chen; Wen Fu; Xiaoqian Tian; Susu Lou; Jichen Ruan; Jing He; Haixia Zhou
Journal:  J Clin Lab Anal       Date:  2019-07-25       Impact factor: 2.352

4.  A case series of intestinal adenomatous polyposis of unidentified etiology; a late effect of irradiation?

Authors:  Lisanne Sara Rigter; Frank G J Kallenberg; Barbara Bastiaansen; Theo A M van Os; Floor E van Leeuwen; Monique Esther van Leerdam; Evelien Dekker
Journal:  BMC Cancer       Date:  2016-11-08       Impact factor: 4.430

5.  Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms' Tumor in Childhood.

Authors:  Linda Kievit; Pia Kræmer; Stephen Hamilton-Dutoit; Henning Grønbæk
Journal:  Case Rep Gastroenterol       Date:  2018-02-01

6.  Unusual presentation of a hepatocellular carcinoma as a potential late side effect of radiotherapy in a patient treated for Wilms tumor in childhood.

Authors:  Deborah Repullo; Marie Diaz; Stéphane Holbrechts; Maria Gomez-Galdón; Dirk Van Gestel; Ali Bohlok; Gabriel Liberale; Vincent Donckier
Journal:  World J Surg Oncol       Date:  2018-03-07       Impact factor: 2.754

7.  The Dutch LATER physical outcomes set for self-reported data in survivors of childhood cancer.

Authors:  Nina Streefkerk; Wim J E Tissing; Margriet van der Heiden-van der Loo; Elizabeth A M Lieke Feijen; Eline van Dulmen-den Broeder; Jacqueline J Loonen; Helena J H van der Pal; Cécile M Ronckers; Hanneke M van Santen; Marleen H van den Berg; Renée L Mulder; Joke C Korevaar; Leontine C M Kremer
Journal:  J Cancer Surviv       Date:  2020-05-03       Impact factor: 4.442

8.  Genes Controlled by DNA Methylation Are Involved in Wilms Tumor Progression.

Authors:  João Victor da Silva Guerra; Bruna Maria de Sá Pereira; Jéssica Gonçalves Vieira da Cruz; Nicole de Miranda Scherer; Carolina Furtado; Rafaela Montalvão de Azevedo; Paulo Sergio Lopes de Oliveira; Paulo Faria; Mariana Boroni; Beatriz de Camargo; Mariana Maschietto
Journal:  Cells       Date:  2019-08-17       Impact factor: 6.600

9.  Treatment and outcome of the patients with rhabdomyosarcoma of the biliary tree: Experience of the Cooperative Weichteilsarkom Studiengruppe (CWS).

Authors:  Cristian Urla; Steven W Warmann; Monika Sparber-Sauer; Andreas Schuck; Ivo Leuschner; Thomas Klingebiel; Gunnar Blumenstock; Guido Seitz; Ewa Koscielniak; Jörg Fuchs
Journal:  BMC Cancer       Date:  2019-10-14       Impact factor: 4.430

10.  Identification of a five-mRNA signature as a novel potential prognostic biomarker in pediatric Wilms tumor.

Authors:  Xiao-Dan Lin; Yu-Peng Wu; Shao-Hao Chen; Xiong-Lin Sun; Zhi-Bin Ke; Dong-Ning Chen; Xiao-Dong Li; Yun-Zhi Lin; Yong Wei; Qing-Shui Zheng; Ning Xu; Xue-Yi Xue
Journal:  Mol Genet Genomic Med       Date:  2019-11-07       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.